---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-078584"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T04:52:56.332416+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NeuroOne amends CEO & three other execs' change-in-control severance benefits

## Summary
- CEO Rosa: 2.0x base salary + 2.0x target bonus lump sum, full equity vest, 24-month COBRA upon qualifying termination.
- CFO McClurg, COO Volker, CTO Mertens: 1.25x base + 1.25x bonus lump sum, full vest, 15-month COBRA.
- Amendments effective Sep 9, 2024; apply to terminations within 12 months after or 3 months before a change in control.
- Benefit conditioned on signing a release and ongoing compliance; all other employment terms unchanged.

## SEC filing metadata
- accession: 0001213900-24-078584
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390024078584/0001213900-24-078584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390024078584/ea0214149-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-078584
- JSON: https://secwatch.observer/filing/0001213900-24-078584.json
- Plain text: https://secwatch.observer/filing/0001213900-24-078584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.